All In Biotech

Drug Trial Radar · NCT04686305

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 304 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

304

Planned (sponsor's estimate)

Start

Mar 9, 2021

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Dec 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-small cell lung cancer. The efficacy will be also analyzed as a secondary endpoint.

Conditions

  • Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions

  • T-DXdDrug

    T-DXd: administered as an IV infusion

  • DurvalumabBiological

    Durvalumab: administered as an IV infusion

  • CisplatinDrug

    Cisplatin: administered as an IV infusion

  • CarboplatinDrug

    Carboplatin: administered as an IV infusion

  • PemetrexedDrug

    Pemetrexed: administered as an IV infusion (drug not used)

  • VolrustomigDrug

    Volrustomig: administered as an IV infusion

  • RilvegostomigDrug

    Rilvegostomig: administered as an IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of AEs and SAEsTime frame: Safety and tolerability (and to determine RP2D) will be assessed for approximately 20 months from informed consent

Locations

91 sites in 19 countries. Site status is shown where the registry gives one.

  • Research Site

    Duarte, California · Withdrawn

  • Research Site

    Newport Beach, California · Withdrawn

  • Research Site

    Orange, California · Recruiting

  • Research Site

    Santa Rosa, California · Withdrawn

  • Research Site

    Westwood, Kansas · Withdrawn

  • Research Site

    Baltimore, Maryland · Recruiting

  • Research Site

    Detroit, Michigan · Withdrawn

  • Research Site

    Buffalo, New York · Withdrawn

  • Research Site

    New York, New York · Withdrawn

  • Research Site

    The Bronx, New York · Withdrawn

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Fairfax, Virginia · Recruiting

  • Research Site

    Tacoma, Washington · Withdrawn

  • Research Site

    Adelaide, Australia · Terminated

  • Research Site

    Heidelberg, Australia · Withdrawn

  • Research Site

    Nedlands, Australia · Recruiting

  • Research Site

    Edegem, Belgium · Completed

  • Research Site

    Barretos, Brazil · Recruiting

  • Research Site

    Porto Alegre, Brazil · Recruiting

  • Research Site

    São Paulo, Brazil · Recruiting

  • Research Site

    Winnipeg, Manitoba, Canada · Withdrawn

  • Research Site

    London, Ontario, Canada · Withdrawn

  • Research Site

    Montreal, Quebec, Canada · Recruiting

  • Research Site

    Changchun, China · Not yet recruiting

  • Research Site

    Chengdu, China · Not yet recruiting

  • Research Site

    Fuzhou, China · Not yet recruiting

  • Research Site

    Shandong, China · Not yet recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Zhengzhou, China · Not yet recruiting

  • Research Site

    Bordeaux, France · Withdrawn

  • Research Site

    Dijon, France · Recruiting

  • Research Site

    Pierre-Bénite, France · Recruiting

  • Research Site

    Saint-Herblain, France · Recruiting

  • Research Site

    Villejuif, France · Recruiting

  • Research Site

    Kfar Saba, Israel · Recruiting

  • Research Site

    Tel HaShomer, Israel · Recruiting

  • Research Site

    Milan, Italy · Completed

  • Research Site

    Milan, Italy · Recruiting

  • Research Site

    Monza, Italy · Recruiting

  • Research Site

    Naples, Italy · Recruiting

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.